Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) will present updated Phase 2a survival data for atebimetinib plus mGnP in first-line pancreatic cancer at the 2026 ASCO Annual Meeting.
The oral presentation covers an expanded cohort of 55 first-line patients and is scheduled for June 1, 2026, 1:15 PM CDT, presented by Dr. Peter Vu.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – IMRX
On the day this news was published, IMRX gained 4.14%, reflecting a moderate positive market reaction. This price movement added approximately $15M to the company's valuation, bringing the market cap to $381.07M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IMRX slipped 0.54% while peers showed mixed moves: several biotech names like ASMB (-3.76%) and FULC (-3.52%) declined, but LRMR rose 0.84%, suggesting stock-specific trading rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Genetic data update | Positive | -0.5% | AACR ctDNA data suggesting reduced MAPK-driven resistance with atebimetinib. |
| Apr 06 | Conference appearance | Neutral | -3.1% | Announcement of CEO fireside chat at Needham healthcare conference. |
| Mar 17 | Molecular data preview | Positive | -0.4% | Plan to present AACR molecular data on atebimetinib-treated RAS-mutant tumors. |
| Mar 06 | Earnings & clinical | Positive | +7.0% | Q4/FY 2025 results plus Phase 2a survival data and cash runway update. |
| Mar 02 | Conference appearance | Neutral | -1.0% | Planned Leerink Global Healthcare Conference fireside chat and 1x1 meetings. |
Recent scientific and conference-related news often saw modest or negative price reactions, while the detailed earnings/clinical update on Mar 6, 2026 coincided with a stronger positive move.
Over the last two months, Immuneering has repeatedly highlighted atebimetinib’s potential in first-line pancreatic cancer. On Mar 6, 2026, full-year 2025 results and Phase 2a survival data drove a 7.03% gain. Subsequent AACR molecular and genetic data updates on Mar 17 and Apr 20 were followed by small declines of 0.42% and 0.54%. Multiple conference presentations (Leerink, Needham) drew limited positive reaction. Today’s ASCO oral presentation announcement adds another visibility milestone for the same program.
Regulatory & Risk Context
Immuneering has an active Form S-3 filed on Aug 13, 2025, registering up to $300,000,000 of securities. The shelf includes an equity distribution agreement for up to $100,000,000 of Class A common stock with Piper Sandler & Co., and has been used at least twice via 424B5 filings dated Sep 24 and Sep 25, 2025.
Market Pulse Summary
This announcement highlights progression of Immuneering’s pancreatic cancer program, with updated survival data from an expanded 55-patient Phase 2a cohort to be showcased in an ASCO oral session. It builds on earlier molecular and survival findings already disclosed in recent months. Investors may watch for detailed efficacy, durability, and tolerability metrics from the presentation and how they compare with the previously reported 34-patient cohort as the company advances toward later‑stage trials.
Key Terms
phase 2a medical
modified gemcitabine/nab-paclitaxel medical
metastatic pancreatic cancer medical
asco medical
AI-generated analysis. Not financial advice.
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -
- The ASCO presentation will highlight data from an expanded cohort totaling 55 first-line patients -
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that updated data from the Phase 2a clinical trial evaluating atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients will be presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.
The oral presentation will highlight data from an expanded cohort totaling 55 first-line patients, which includes the initial cohort of 34 patients that the company previously reported plus an additional 21 patients.
“We are excited to present new survival data from an expanded cohort of 55 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in an oral presentation at ASCO,” said Ben Zeskind, Ph.D., CEO of Immuneering. “Atebimetinib was designed with three distinct mechanisms to promote survival: shrinking tumors durably, preserving body mass, and maximizing tolerability. We believe these mechanisms have the potential to both yield the best survival in the first-line setting, and to give patients the best chance of reaching and benefitting from second-line treatment. We look forward to sharing this updated dataset in first-line pancreatic cancer patients as we pursue our mission to help patients survive and thrive.”
Oral Presentation Details:
Title: Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer
Session Type/Title: Rapid Oral Abstract Session – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract Number: 4013
Date and Time: June 1, 2026, 1:15 p.m. – 2:45 p.m. CDT
Presenter: Peter Vu, MD, MHA
About Immuneering
Immuneering is a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. The company expects to dose the first patient in mid-2026 in MAPKeeper 301, a globally randomized pivotal Phase 3 trial evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and early-stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and its potential to deliver overall survival with both durability and tolerability; the timing of dosing of the MAPKeeper 301 study; the content of the upcoming 2026 oral presentation at ASCO; the ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the period ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Courtney Dugan
Cdugan@immuneering.com
Media Contact:
Peg Rusconi
Peg.rusconi@deerfieldgroup.com
